Premium
Levels of circulating immune complexes in patients with ovarian cancer
Author(s) -
CLARKE ANN G.,
VASEY D. P.,
SYMONDS E. M.,
FARATIAN B.,
McLAUGHLIN P. J.,
PRICE M. R.,
BALDWIN R. W.
Publication year - 1982
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1982.tb03621.x
Subject(s) - ovarian cancer , immune system , medicine , cancer , oncology , cancer research , immunology
Summary. Sera from patients with ovarian tumours were assayed for circulating immune complexes (CIC) by four well established assays based on the interaction of immune complexes with components of the complement system. There was no difference in control, pre‐ or post‐operative or BCG‐treated patients' sera. Levels were also unchanged in sera in antigen excess. In patients with ovarian tumours therefore the measurement of CIC would appear to be of little value as a screening test, as a guide to the extent of disease, prognosis or therapy. In a small pilot therapy‐trial there was no difference in the survival rate between patients with stage III and IV ovarian cancer treated with cyclophosphamide plus BCG and those who received only cyclophosphamide. Treatment with BCG was associated with postoperative pyrexia and a prolonged hospital stay.